<![CDATA[Chugai Pharmaceutical: News Releases]]> https://www.chugai-pharm.co.jp/english/index.html en-us Wed, 30 Sep 2026 15:30:00 +0900 <![CDATA[Establishment of a Subsidiary in South Korea]]> https://www.chugai-pharm.co.jp/english/news/detail/20260930153000_1290.html Wed, 30 Sep 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260930153000_1290.html <![CDATA[Chugai and InxMed Enter into a Worldwide License Agreement for SPYK04, a RAF-MEK Molecular Glue]]> https://www.chugai-pharm.co.jp/english/news/detail/20260929170000_1254.html Tue, 29 Sep 2026 17:00:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260929170000_1254.html <![CDATA[Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA]]> https://www.chugai-pharm.co.jp/english/news/detail/20260928160000_1289.html Mon, 28 Sep 2026 16:00:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260928160000_1289.html <![CDATA[Roche’s Announcement Regarding Sefaxersen (Announcement of Interim Analysis Results from the Phase III IMAGINATION Study) ]]> https://www.chugai-pharm.co.jp/english/news/detail/20260924153000_1288.html Thu, 24 Sep 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260924153000_1288.html <![CDATA[Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lorlatinib for ALK Fusion Gene-Positive Non-Small Cell Lung Cancer]]> https://www.chugai-pharm.co.jp/english/news/detail/20260918153000_1286.html Fri, 18 Sep 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260918153000_1286.html <![CDATA[Roche Announces Phase III CELESTIMO Study Results for Lunsumio in Relapsed or Refractory Follicular Lymphoma]]> https://www.chugai-pharm.co.jp/english/news/detail/20260917153000_1287.html Thu, 17 Sep 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260917153000_1287.html <![CDATA[Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Tovorafenib for BRAF V600 Alterations and BRAF Fusion Gene-Positive Glioma]]> https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html Wed, 16 Sep 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html <![CDATA[Personnel Changes]]> https://www.chugai-pharm.co.jp/english/news/detail/20260914153000_1285.html Mon, 14 Sep 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260914153000_1285.html